{"id":"W4324136701","doi":"10.1200/jco.2023.41.6_suppl.508","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Avelumab; Randomization; Regimen; Internal medicine; Metastatic Urothelial Carcinoma; Clinical endpoint; Chemotherapy; Oncology; Maintenance therapy; Chemotherapy regimen; Cisplatin; Urology; Surgery; Bladder cancer; Randomized controlled trial; Cancer; Nivolumab; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005405128,0.0007937506,0.001813375,0.0003956979,0.0005015884,0.001085628,0.0008753238,0.001206649,0.002836945],"category_scores_gemma":[0.002555131,0.0004699465,0.002765188,0.0005537717,0.0009235462,0.001044721,0.0007175068,0.002372167,0.0004110666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001055578,"about_ca_system_score_gemma":0.001193142,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000740058,"about_ca_topic_score_gemma":0.002744615,"domain_scores_codex":[0.9985985,0.0007918196,0.00008731319,0.0002217106,0.0001239096,0.0001768284],"domain_scores_gemma":[0.9975744,0.0005880829,0.0007352302,0.0003423262,0.0001103368,0.0006495764],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9483452,0.00649569,0.01738841,0.0004540344,0.002650005,0.00006641485,0.0001115899,0.0008527181,0.003672497,0.00006619796,0.001386464,0.01851067],"study_design_scores_gemma":[0.5461858,0.2959469,0.1396354,0.0001597027,0.008306488,0.000305502,0.0001264712,0.001848725,0.003316538,0.0004676597,0.003604391,0.00009647727],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940006,0.002106638,0.0003262716,0.0002183422,0.00005800265,0.0008579649,0.001641385,0.00003097199,0.0007599263],"genre_scores_gemma":[0.9911152,0.0006932344,0.0006798173,0.0004643511,0.0001043667,0.001407159,0.004403954,0.00001415688,0.001117807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005405128,"threshold_uncertainty_score":0.02858537,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07867984464162421,"score_gpt":0.3967172159134745,"score_spread":0.3180373712718503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}